Early diagnosis of IPF: time for a primary-care case-finding initiative?

Idiopathic pulmonary fibrosis (IPF) is a seriously under recognised problem for public health. It is not widely appreciated that, if classified as a malignancy, IPF would rank as the eighth most prevalent cancer worldwide. By the time diagnosis is made, average survival is little better than that for inoperable lung cancer. Indirect evidence suggests that early expert evaluation is important. After the onset of exertional dyspnoea, delayed referral to a tertiary care centre is associated with increased mortality, independent of disease severity.1 In the placebo groups of recent treatment trials, in which comorbidities such as infection and gastro-oesophageal regurgitation were managed and monitored by specialist clinicians, outcomes were considerably better than would be expected from historical data

Bigliografia :

Fonti :

mer 12 marzo 2014
VEDI ANCHE
Parliamo di …